title: Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy.
abstract: In 19 patients with hypertrophic cardiomyopathy (15 males, 4 females, mean age 49.2 +/- 10.8 years) left ventricular function was studied with radionuclide ventriculography at rest and during exercise in a crossover design without intervention and after disopyramide and propranolol treatment. 15 of the 19 patients had a resting or latent intraventricular gradient of more than 30 mm Hg. Left ventricular function at rest and during exercise was evaluated before medication, 90 min after oral administration of 200 mg disopyramide or 160 mg propranolol and after 3 weeks of oral therapy with disopyramide 200 mg 2 times a day or propranolol 80 mg 4 times a day. After long-term treatment with disopyramide, resting ejection fraction decreased from 72 +/- 12 to 69 +/- 14% (p less than 0.01) and peak ejection rate (PER) decreased from 3.46 +/- 135 to 3.24 +/- 65 end-diastolic volume (EDV).s-1 (p less than 0.01). Peak filling rate (PFR) at rest decreased from 3.01 +/- 0.8 to 2.77 +/- 0.63 EDV.s-1 (p less than 0.05). Time to peak filling rate (TPFR) at rest and during exercise after acute and chronic therapy did not change compared to control values. Acute and long-term administration of propranolol lead to a significant reduction in heart rate at rest and during exercise.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, Johann Wolfgang Goethe-University, Medical School, Frankfurt, FRG.
authors.forename: A
authors.initials: A
authors.lastname: Hartmann
authors.forename: J
authors.initials: J
authors.lastname: Kühn
authors.forename: R
authors.initials: R
authors.lastname: Hopf
authors.forename: H
authors.initials: H
authors.lastname: Klepzig
authors.forename: R
authors.initials: R
authors.lastname: Standke
authors.forename: G
authors.initials: G
authors.lastname: Kober
authors.forename: F D
authors.initials: FD
authors.lastname: Maul
authors.forename: G
authors.initials: G
authors.lastname: Hör
authors.forename: M
authors.initials: M
authors.lastname: Kaltenbach
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy* / Q000503:physiopathology; D004206:Disopyramide / Q000627:therapeutic use*; D004452:Echocardiography / Q000187:drug effects; D005080:Exercise Test / Q000187:drug effects*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007275:Injections, Intravenous; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use*; D015635:Radionuclide Ventriculography / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
chemical_list: D011433:Propranolol; D004206:Disopyramide